Myotonic dystrophy is a genetic disorder that occurs due to mutation in DMPK gene and CNBP gene which affects the functioning of muscles and other body systems. People having myotonic dystrophy have progressive weakness of muscles in hands, legs, face, and neck which get worse over time. There are two types of myotonic dystrophy, myotonic dystrophy type I and myotonic dystrophy type II. Myotonic dystrophy can be diagnosed by genetic test, physical exam, and electromyography. It has been observed that myotonic dystrophy type I is severe than myotonic dystrophy type II. AMO Pharma Limited is in the process of developing tideglusib as a glycogen synthase kinase 3 beta inhibitor, for the treatment of myotonic dystrophy. Gilead Sciences, Inc. is also in the process of developing ranolazine as a P-glycoprotein inhibitor, for the treatment of myotonic dystrophy. Some of the companies having the pipeline of myotonic dystrophy include AMO Pharma Limited, Valerion Therapeutics, LLC, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.